VAV1 and acute myeloid leukemia: We found that the percentage of recipients of Fh1fl/fl;FHCyt;Vav-iCre cells that developed terminal AML was significantly reduced (and the disease latency was extended) compared with recipients of control and control;FHCyt cells (Fig. 6 C).